United States HR 7640: To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Status: Introduced in House (as of 2022-05-03)

State: United States · Session: 117 · Bill: HR 7640

Sponsors: Gus M. Bilirakis, G. K. Butterfield

View United States HR 7640 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.